Moreover, as increasing evidence shows that KRAS mutations correlate with unresponsiveness to EGFR inhibitors [21], we tested the biological activity of DSF-102 in a lung adenocarcinoma cell line, the A549 KRAS mutant cells. The gene discussed is KRAS; the disease is lung adenocarcinoma.